Antisoma buoyed by AS1404 survival benefit

摘要

Antisoma's vascular targeting agent AS1404 is looking increasingly promising with final data from a Phase II trial showing a substantial increase in survival in advanced non-small-cell lung cancer patients.Of 70 evaluable patients with stage 1Mb or IV disease, those who received AS1404 on top of standard chemotherapy (carboplatin plus paclitaxel) had a median survival of 14.0 months compared with 8.8 months in patients on chemotherapy alone, the company said. It added that this was one of the largest improvements ever seen in a randomised controlled trial with a novel agent in the first-line treatment of lung cancer. Overall, patients on AS1404 had a 27% lower risk of dying than those on chemotherapy alone, it said.